AIM: Embryonic tumors are associated with an interruption during normal organ development; they may be related to disturbances in the folate pathway involved in DNA synthesis, methylation, and repair. Prenatal supplementation with folic acid is associated with a decreased risk of neuroblastoma, brain tumors, retinoblastoma, and nephroblastoma. The aim of this study was to investigate the association between MTHFR rs1801133 (C677T) and RFC-1 rs1051266 (G80A) genotypes with the risk of developing nephroblastoma and neuroblastoma. MATERIALS AND METHODS: Case-mother/control-mother dyad study. Samples from Brazilian children with nephroblastoma (n=80), neuroblastoma (n=66), healthy controls (n=453), and their mothers (case n=93; control n=75) were analyzed. Genomic DNA was isolated from peripheral blood cells and/or buccal cells and genotyped to identify MTHFR C677T and RFC-1 G80A polymorphisms. Differences in genotype distribution between patients and controls were tested by multiple logistic regression analysis. RESULTS: Risk for nephroblastoma and neuroblastoma was two- to fourfold increased among children with RFC-1 polymorphisms. An increased four- to eightfold risk for neuroblastoma and nephroblastoma was seen when the child and maternal genotypes were combined. CONCLUSION: Our results suggest that mother and child RFC-1 G80A genotypes play a role on the risk of neuroblastoma and nephroblastoma since this polymorphism may impair the intracellular levels of folate, through carrying fewer folate molecules to the cell interior, and thus, the intracellular concentration is not enough to maintain regular DNA synthesis and methylation pathways.
AIM: Embryonic tumors are associated with an interruption during normal organ development; they may be related to disturbances in the folate pathway involved in DNA synthesis, methylation, and repair. Prenatal supplementation with folic acid is associated with a decreased risk of neuroblastoma, brain tumors, retinoblastoma, and nephroblastoma. The aim of this study was to investigate the association between MTHFRrs1801133 (C677T) and RFC-1rs1051266 (G80A) genotypes with the risk of developing nephroblastoma and neuroblastoma. MATERIALS AND METHODS: Case-mother/control-mother dyad study. Samples from Brazilian children with nephroblastoma (n=80), neuroblastoma (n=66), healthy controls (n=453), and their mothers (case n=93; control n=75) were analyzed. Genomic DNA was isolated from peripheral blood cells and/or buccal cells and genotyped to identify MTHFR C677T and RFC-1 G80A polymorphisms. Differences in genotype distribution between patients and controls were tested by multiple logistic regression analysis. RESULTS: Risk for nephroblastoma and neuroblastoma was two- to fourfold increased among children with RFC-1 polymorphisms. An increased four- to eightfold risk for neuroblastoma and nephroblastoma was seen when the child and maternal genotypes were combined. CONCLUSION: Our results suggest that mother and childRFC-1 G80A genotypes play a role on the risk of neuroblastoma and nephroblastoma since this polymorphism may impair the intracellular levels of folate, through carrying fewer folate molecules to the cell interior, and thus, the intracellular concentration is not enough to maintain regular DNA synthesis and methylation pathways.
Authors: Iêda Maria Orioli; Ricardo Lima do Nascimento; Jorge Santiago López-Camelo; Eduardo Enrique Castilla Journal: Birth Defects Res A Clin Mol Teratol Date: 2011-05-31
Authors: R J Berry; Z Li; J D Erickson; S Li; C A Moore; H Wang; J Mulinare; P Zhao; L Y Wong; J Gindler; S X Hong; A Correa Journal: N Engl J Med Date: 1999-11-11 Impact factor: 91.245
Authors: B C Blount; M M Mack; C M Wehr; J T MacGregor; R A Hiatt; G Wang; S N Wickramasinghe; R B Everson; B N Ames Journal: Proc Natl Acad Sci U S A Date: 1997-04-01 Impact factor: 11.205
Authors: Dyego O de Miranda; Jemima E X S Barros; Maria Madalena S Vieira; Elker L S Lima; Vera L L Moraes; Helker A da Silva; Helder L B O Garcia; Cássia A Lima; Adriana V Gomes; Neide Santos; Maria T C Muniz Journal: Mol Biol Rep Date: 2014-04-27 Impact factor: 2.316
Authors: Flavio Jose da Costa Ramos; Maria Tereza Cartaxo Muniz; Vanessa Cavalcante Silva; Marcela Araújo; Ednalva Pereira Leite; Elizabete Malaquias Freitas; Crisiane Wais Zanrosso; Ana Hatagima; Maricilda Palandi de Mello; Jose Andrés Yunes; Terezinha de Jesus Marques-Salles; Neide Santos; Silvia R Brandalise; Maria S Pombo-De-Oliveira Journal: Leuk Lymphoma Date: 2006-10
Authors: Amy E French; Ron Grant; Sheila Weitzman; Joel G Ray; Marian J Vermeulen; Lillian Sung; Mark Greenberg; Gideon Koren Journal: Clin Pharmacol Ther Date: 2003-09 Impact factor: 6.875
Authors: Angela L Mazul; Anna Maria Siega-Riz; Clarice R Weinberg; Stephanie M Engel; Fei Zou; Kathryn S Carrier; Patricia V Basta; Zalman Vaksman; John M Maris; Sharon J Diskin; Charlene Maxen; Arlene Naranjo; Andrew F Olshan Journal: Cancer Causes Control Date: 2016-08-19 Impact factor: 2.506